Weight loss jab that's even better than Wegovy approved in UK
페이지 정보
본문
A drug hailed as the ‘King Kong' of weight loss jabs is being given to diabetics on the NHS.
Around 180,000 people with type 2 diabetes are set to be given tirzepatide to help control their condition.
Taken as a once-weekly jab, it was given the green light for patients who cannot tolerate metformin - the first-line medicine for type 2 diabetes - once stocks become available.
The National Institute for Health and Care Excellence (Nice) today recommended it as a diabetic medication, to be prescribed alongside diet and exercise.
It could be available as early as October, dependent on supply by the US pharmaceutical giant Eli Lilly.
Tirzepatide, sold under the brand name Mounjaro, has been approved for "https://wiki.gem-flash.com/index.php?title=User:NancyLeGrand use for diabetics in the NHS
The above graphic shows how weight-loss drug tirzepatide works. It works to suppress hunger by mimicking hormones indicating that the body is full. It also shows the passage of food through the stomach by reducing the production of stomach acid and contractions of the muscle
A decision on its use for weight loss is expected within months.
The once weekly jab is a class of drugs called GLP-1 agonists, which mimic a hormone that helps suppress the appetite, reducing food intake.
Trials also found it boosts the production of insulin, the hormone that regulates blood sugar, essential to control type 2 diabetes.
After just a year, a third of type 2 diabetics taking the drug lost more than 20 per cent of their body weight, significantly more than rivals.
It led US diabetes expert Dr Julio Rosenstock to declare it ‘King Kong' compared to ‘the gorilla' of semaglutide, the key ingredient in Wegoby and Ozempic.
Around 180,000 people with type 2 diabetes are set to be given tirzepatide to help control their condition.
Taken as a once-weekly jab, it was given the green light for patients who cannot tolerate metformin - the first-line medicine for type 2 diabetes - once stocks become available.
The National Institute for Health and Care Excellence (Nice) today recommended it as a diabetic medication, to be prescribed alongside diet and exercise.
It could be available as early as October, dependent on supply by the US pharmaceutical giant Eli Lilly.
Tirzepatide, sold under the brand name Mounjaro, has been approved for "https://wiki.gem-flash.com/index.php?title=User:NancyLeGrand use for diabetics in the NHS
The above graphic shows how weight-loss drug tirzepatide works. It works to suppress hunger by mimicking hormones indicating that the body is full. It also shows the passage of food through the stomach by reducing the production of stomach acid and contractions of the muscle
A decision on its use for weight loss is expected within months.
The once weekly jab is a class of drugs called GLP-1 agonists, which mimic a hormone that helps suppress the appetite, reducing food intake.
Trials also found it boosts the production of insulin, the hormone that regulates blood sugar, essential to control type 2 diabetes.
After just a year, a third of type 2 diabetics taking the drug lost more than 20 per cent of their body weight, significantly more than rivals.
It led US diabetes expert Dr Julio Rosenstock to declare it ‘King Kong' compared to ‘the gorilla' of semaglutide, the key ingredient in Wegoby and Ozempic.
- 이전글Title: Pablo Snus: Unleash a Refreshing Breeze of Flavors and Nicotine Satisfaction 23.09.12
- 다음글Diplom 23.08.12